As the Kansas City Chiefs chase their third straight Super Bowl, the officials from their Divisional Round postseason win over the Houston Texans have been in the news for the wrong reasons. Clay ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $70.37.

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Quest Diagnostics (NYSE:DGX) from Market Perform to Outperform. Analyst Price Forecast Suggests 15.27% Upside As of ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

On Friday, Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 21.94% ...